Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of eomesodermin

Journal of Experimental Medicine

Volumn 210, Issue 4, 2013, Pages 743-755

  Curran, Michael A ^a   Geiger, Theresa L ^b   Montalvo, Welby ^b   Kim, Myoungjoo ^b   Reiner, Steven L ^c,d   Al Shamkhani, Aymen ^e   Sun, Joseph C ^b   Allison, James P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Department of Microbiology and Immunology ^*  (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD4 ANTIGEN; EOMESODERMIN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 27; CYTOKINE; EOMES PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; KLRG1 PROTEIN, MOUSE; T BOX TRANSCRIPTION FACTOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CELL LINEAGE; CELL POLARITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY; HEPATITIS; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS HEPATITIS; ANIMAL; AUTOIMMUNITY; BIOSYNTHESIS; CYTOLOGY; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MELANOMA; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD137; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; GENE EXPRESSION REGULATION; MELANOMA; MICE; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC; T-BOX DOMAIN PROTEINS;

MLCS; MLOWN;

EID: 84878648242     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20121190     Document Type: Article

References (48)

1. Bots, M., I.G. Kolfschoten, S.A. Bres, M.T. Rademaker, G.M. de Roo, M. Krüse, K.L. Franken, M. Hahne, C.J. Froelich, C.J. Melief, et al. 2005. SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. Blood. 105:1153-1161. http://dx.doi.org/10.1182/blood-2004-03-0791
2. Choi, B.K., T. Asai, D.S. Vinay, Y.H. Kim, and B.S. Kwon. 2006. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine. 34:233-242. http://dx.doi.org/10.1016/j.cyto.2006.04.008
3. Choi, B.K., Y.H. Kim, P.M. Kwon, S.C. Lee, S.W. Kang, M.S. Kim, M.J. Lee, and B.S. Kwon. 2009. 4-1BB functions as a survival factor in dendritic cells. J. Immunol. 182:4107-4115. http://dx.doi.org/10.4049/jimmunol.0800459
4. Collins, P.L., S. Chang, M. Henderson, M. Soutto, G.M. Davis, A.G. McLoed, M.J. Townsend, L.H. Glimcher, D.P. Mortlock, and T.M. Aune. 2010. Distal regions of the human IFNG locus direct cell typespecific expression. J. Immunol. 185:1492-1501. http://dx.doi.org/10.4049/jimmunol.1000124
5. Curran, M.A., and J.P. Allison. 2009. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 69:7747-7755. http://dx.doi.org/10.1158/0008-5472.CAN-08-3289
6. Curran, M.A., M. Kim, W. Montalvo, A. Al-Shamkhani, and J.P. Allison. 2011. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS ONE. 6:e19499. http://dx.doi.org/10.1371/journal.pone.0019499
7. DeBenedette, M.A., A. Shahinian, T.W. Mak, and T.H. Watts. 1997. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J. Immunol. 158:551-559.
8. Diveu, C., M.J. McGeachy, K. Boniface, J.S. Stumhofer, M. Sathe, B. Joyce-Shaikh, Y. Chen, C.M. Tato, T.K. McClanahan, R. de Waal Malefyt, et al. 2009. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. 182:5748-5756. http://dx.doi.org/10.4049/jimmunol.0801162
9. Dubrot, J., F. Milheiro, C. Alfaro, A. Palazón, I. Martinez-Forero, J.L. Perez-Gracia, A. Morales-Kastresana, J.L. Romero-Trevejo, M.C. Ochoa, S. Hervás-Stubbs, et al. 2010. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol. Immunother. 59:1223-1233. http://dx.doi.org/10.1007/s00262-010-0846-9
10. Futagawa, T., H. Akiba, T. Kodama, K. Takeda, Y. Hosoda, H. Yagita, and K. Okumura. 2002. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14:275-286. http://dx.doi.org/10.1093/intimm/14.3.275
11. Hernandez-Chacon, J.A., Y. Li, R.C. Wu, C. Bernatchez, Y. Wang, J.S. Weber, P. Hwu, and L.G. Radvanyi. 2011. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J. Immunother. 34:236-250. http://dx.doi.org/10.1097/CJI.0b013e318209e7ec
12. Herrero, C., X. Hu, W.P. Li, S. Samuels, M.N. Sharif, S. Kotenko, and L.B. Ivashkiv. 2003. Reprogramming of IL-10 activity and signaling by IFN-gamma. J. Immunol. 171:5034-5041.
13. + T cells is associated with concomitant memory and terminally differentiated phenotype. J. Exp. Med. 209:2113-2126. http://dx.doi.org/10.1084/jem.20120532
14. Huber, M., V. Steinwald, A. Guralnik, A. Brüstle, P. Kleemann, C. Rosenplänter, T. Decker, and M. Lohoff. 2008. IL-27 inhibits the development of regulatory T cells via STAT3. Int. Immunol. 20:223-234. http://dx.doi.org/10.1093/intimm/dxm139
15. Hurtado, J.C., Y.J. Kim, and B.S. Kwon. 1997. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation- induced cell death. J. Immunol. 158:2600-2609.
16. Ichiyama, K., T. Sekiya, N. Inoue, T. Tamiya, I. Kashiwagi, A. Kimura, R. Morita, G. Muto, T. Shichita, R. Takahashi, and A. Yoshimura. 2011. Transcription factor Smad-independent T helper 17 cell induction by transforming- growth factor-β is mediated by suppression of eomesodermin. Immunity. 34:741-754. http://dx.doi.org/10.1016/j.immuni.2011.02.021
17. Intlekofer, A.M., A. Banerjee, N. Takemoto, S.M. Gordon, C.S. Dejong, H. Shin, C.A. Hunter, E.J. Wherry, T. Lindsten, and S.L. Reiner. 2008. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science. 321:408-411. http://dx.doi.org/10.1126/science.1159806
18. Johnston, J.A., C.M. Bacon, D.S. Finbloom, R.C. Rees, D. Kaplan, K. Shibuya, J.R. Ortaldo, S. Gupta, Y.Q. Chen, J.D. Giri, et al. 1995. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc. Natl. Acad. Sci. USA. 92:8705- 8709. http://dx.doi.org/10.1073/pnas.92.19.8705
19. Ju, S.A., S.M. Park, S.C. Lee, B.S. Kwon, and B.S. Kim. 2007. Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody. Mol. Cells. 24:132-138.
20. Kim, Y.H., B.K. Choi, S.M. Shin, C.H. Kim, H.S. Oh, S.H. Park, D.G. Lee, M.J. Lee, K.H. Kim, D.S. Vinay, and B.S. Kwon. 2011. 4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells. J. Immunol. 187:1120-1128. http://dx.doi.org/10.4049/jimmunol.1002681
21. Kocak, E., K. Lute, X. Chang, K.F. May Jr., K.R. Exten, H. Zhang, S.F. Abdessalam, A.M. Lehman, D. Jarjoura, P. Zheng, and Y. Liu. 2006. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66:7276-7284. http://dx.doi.org/10.1158/0008-5472.CAN-05-2128
22. Kwon, B.S., J.C. Hurtado, Z.H. Lee, K.B. Kwack, S.K. Seo, B.K. Choi, B.H. Koller, G. Wolisi, H.E. Broxmeyer, and D.S. Vinay. 2002. Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. 168: 5483-5490.
23. Lee, J., E.N. Lee, E.Y. Kim, H.J. Park, C.Y. Chang, D.Y. Jung, S.Y. Choi, S.K. Lee, K.W. Lee, G.Y. Kwon, et al. 2005a. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol. Lett. 101:210-216. http://dx.doi.org/10.1016/j.imlet.2005.06.001
24. Lee, S.C., S.A. Ju, H.N. Pack, S.K. Heo, J.H. Suh, S.M. Park, B.K. Choi, B.S. Kwon, and B.S. Kim. 2005b. 4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection. Infect. Immun. 73:5144- 5151. http://dx.doi.org/10.1128/IAI.73.8.5144-5151.2005
25. Li, B., J. Lin, M. Vanroey, M. Jure-Kunkel, and K. Jooss. 2007. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin. Immunol. 125:76-87. http://dx.doi.org/10.1016/j.clim.2007.07.005
26. Lin, G.H., B.J. Sedgmen, T.J. Moraes, L.M. Snell, D.J. Topham, and T.H. Watts. 2009. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J. Immunol. 182:934-947.
27. Lin, G.H., Y. Liu, T. Ambagala, B.S. Kwon, P.S. Ohashi, and T.H. Watts. 2010. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS ONE. 5:e11003. http://dx.doi.org/10.1371/journal.pone.0011003
28. + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA. 100:15047-15052. http://dx.doi.org/10.1073/pnas.2536517100
29. Lynch, D.H. 2008. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol. Rev. 222:277- 286. http://dx.doi.org/10.1111/j.1600-065X.2008.00621.x
30. Morishima, N., T. Owaki, M. Asakawa, S. Kamiya, J. Mizuguchi, and T. Yoshimoto. 2005. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J. Immunol. 175: 1686-1693.
31. + T cells. J. Immunol. 183:2435-2443. http://dx.doi.org/10.4049/jimmunol.0900568
32. + T cells. Science. 327:1098-1102. http://dx.doi.org/10.1126/science.1178334
33. Owaki, T., M. Asakawa, N. Morishima, I. Mizoguchi, F. Fukai, K. Takeda, J. Mizuguchi, and T. Yoshimoto. 2008. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J. Immunol. 180:2903-2911.
34. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207:637-650. http://dx.doi.org/10.1084/jem.20091918
35. Qui, H.Z., A.T. Hagymasi, S. Bandyopadhyay, M.C. St Rose, R. Ramanarasimhaiah, A. Ménoret, R.S. Mittler, S.M. Gordon, S.L. Reiner, A.T. Vella, and A.J. Adler. 2011. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J. Immunol. 187:3555-3564. http://dx.doi.org/10.4049/jimmunol.1101244
36. Rao, R.R., Q. Li, K. Odunsi, and P.A. Shrikant. 2010. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity. 32:67-78. http://dx.doi.org/10.1016/j.immuni.2009.10.010
37. Rutishauser, R.L., and S.M. Kaech. 2010. Generating diversity: transcriptional regulation of effector and memory CD8 T-cell differentiation. Immunol. Rev. 235:219-233.
38. Seo, S.K., J.H. Choi, Y.H. Kim, W.J. Kang, H.Y. Park, J.H. Suh, B.K. Choi, D.S. Vinay, and B.S. Kwon. 2004. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10:1088-1094. http://dx.doi.org/10.1038/nm1107
39. Shuai, K., G.R. Stark, I.M. Kerr, and J.E. Darnell Jr. 1993. A single phosphotyrosine residue of Stat91 required for gene activation by interferongamma. Science. 261:1744-1746. http://dx.doi.org/10.1126/science.7690989
40. Shuford, W.W., K. Klussman, D.D. Tritchler, D.T. Loo, J. Chalupny, A.W. Siadak, T.J. Brown, J. Emswiler, H. Raecho, C.P. Larsen, et al. 1997. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47-55. http://dx.doi.org/10.1084/jem.186.1.47
41. Siebler, J., S. Wirtz, C. Frenzel, M. Schuchmann, A.W. Lohse, P.R. Galle, and M.F. Neurath. 2008. Cutting edge: a key pathogenic role of IL-27 in T cell-mediated hepatitis. J. Immunol. 180:30-33.
42. Sun, Y., H.M. Chen, S.K. Subudhi, J. Chen, R. Koka, L. Chen, and Y.X. Fu. 2002a. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. 8:1405-1413. http://dx.doi.org/10.1038/nm1202-796
43. Sun, Y., X. Lin, H.M. Chen, Q. Wu, S.K. Subudhi, L. Chen, and Y.X. Fu. 2002b. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168:1457-1465.
44. Tan, J.T., J.K. Whitmire, R. Ahmed, T.C. Pearson, and C.P. Larsen. 1999. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J. Immunol. 163: 4859-4868.
45. Taraban, V.Y., T.F. Rowley, L. O'Brien, H.T. Chan, L.E. Haswell, M.H. Green, A.L. Tutt, M.J. Glennie, and A. Al-Shamkhani. 2002. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 32:3617-3627. http://dx.doi.org/10.1002/1521-4141(200212)32:12<3617::AIDIMMU3617>3.0.CO;2-M
46. Wang, C., G.H. Lin, A.J. McPherson, and T.H. Watts. 2009. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol. Rev. 229:192-215. http://dx.doi.org/10.1111/j.1600-065X.2009.00765.x
47. Xie, Y., A. Akpinarli, C. Maris, E.L. Hipkiss, M. Lane, E.K. Kwon, P. Muranski, N.P. Restifo, and P.A. Antony. 2010. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207:651-667. http://dx.doi.org/10.1084/jem.20091921
48. Zhao, D.M., S. Yu, X. Zhou, J.S. Haring, W. Held, V.P. Badovinac, J.T. Harty, and H.H. Xue. 2010. Constitutive activation of Wnt signaling favors generation of memory CD8 T cells. J. Immunol. 184:1191-1199. http://dx.doi.org/10.4049/jimmunol.0901199